✦ LIBER ✦

M1 Agonists for the Treatment of Alzheimer's Disease. : Novel Properties and Clinical Update

✍ Scribed by A. FISHER; E. HELDMAN; D. GURWITZ; R. HARING; Y. KARTON; H. MESHULAM; Z. PITTEL; D. MARCIANO; R. BRANDEIS; E. SADOT; Y. BARG; R. PINKAS-KRAMARSKI; Z. VOGEL; I. GINZBURG; T. A. TREVES; R. VERCHOVSKY; S. KLIMOWSKY; A.D. KORCZYN

Book ID: 119873360
Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 453 KB
Volume: 777
Category: Article
ISSN: 0890-6564
DOI: 10.1111/j.1749-6632.1996.tb34418.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Towards the treatment of Alzheimer's dis

Towards the treatment of Alzheimer's disease: Discovery and development of novel subtype-specific M1 allosteric agonists

✍ Lebois, Evan P.; Bridges, Thomas M.; Dawson, Eric S.; Kennedy, J. Phillip; Xiang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Novel m1 muscarinic agonists in treatmen

Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis

✍ Abraham Fisher; Rachel Brandeis; Rachel Haring; Naomi Eshhar; Eliahu Heldman; Yi 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 366 KB

192 Novel m1 muscarinic agonists: From s

192 Novel m1 muscarinic agonists: From symptomatic treatment to delaying the progression of Alzheimer's disease (AD)

✍ A. Fisher; R. Haring; I. Ginzburg; E. Sadot; Z. Pittel; Y. Barg; L. Behar; D. Gu 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 287 KB

Preclinical and Phase 1 clinical charact

Preclinical and Phase 1 clinical characterization of CI-979/ RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease

✍ Allen J. Sedman; Howard Bockbrader; Roy D. Schwarz 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 445 KB

Development of CDD-0102 as a selective M

Development of CDD-0102 as a selective M1 agonist for the treatment of Alzheimer's disease

✍ William S. Messer Jr.; Kenneth A. Bachmann; Colleen Dockery; Afif A. El-Assadi; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

## Abstract Selective muscarinic agonists might be useful in the treatment of Alzheimer's disease. To help characterize the activity and functional selectivity of two M~1~ muscarinic agonists, secretion of amyloid precursor protein, brain penetration, side effect profiles, cognition‐enhancing prope

Talsaclidine (WAL 2014 FU), a muscarinic

Talsaclidine (WAL 2014 FU), a muscarinic M1 receptor agonist for the treatment of Alzheimer's disease

✍ Marion Wienrich; Angelo Ceci; Helmut A. Ensinger; Wolfram Gaida; Klaus D. Mendla 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB